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ABSTRACT 54 
 55 
Bloodstream infections (BSI) are severe diseases associated with a high morbidity and mortality, which 56 
increases with the delay until the administration of the first appropriate antibiotic. For this reason, 57 
empirical treatments, made of broad spectrum antibiotics, are rapidly started when a BSI is suspected on 58 
the basis of the clinical and epidemiological data, but this does not exclude any risk of inappropriate 59 
initial treatment and make the microbial diagnosis crucial. The time to positivity of blood culture, 60 
currently the gold standard to establish the etiology of bloodstream infection can vary from few hours to 61 
several days and using conventional (culture-based) methods, one or more days can be necessary to 62 
determine the etiologic agent of a BSI. Recent advance in molecular biology have permit to develop new 63 
methods to accelerate the microbial diagnosis of BSI. Non-amplified nucleic acid-based methods such as 64 
fluorescent in situ hybridization (FISH) or microarray can be used on positive blood culture whereas 65 
amplified nucleic acid-based methods such as (real-time) PCR or PCR-Electrospray Ionization Mass 66 
Spectrometry (PCR/ESI-MS) can be used directly on whole blood. Matrix-Assisted Laser Desorption 67 
Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF MS), based on the analysis of the mass 68 
spectrum generated by bacterial proteins can be used on positive blood culture. We will present these 69 
technologies and their performance; we will also discuss their advantages and their inconvenient as well 70 
as the question that need to be addressed to fully benefit from these new technologies. 71 
 72 
 73 
 74 
 75 
  76 
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INTRODUCTION 77 
 78 
1. Bloodstream infections  79 
Bloodstream infections (BSI) are severe diseases associated with a high morbidity and mortality, which 80 
increases with the delay until the administration of the first appropriate antibiotic (58; 82; 90; 113; 148; 81 
149; 157; 232). For this reason, empiric treatments made of broad range anti-infectious compounds or 82 
made of a combination of antimicrobials are started immediately after the sampling of blood bottles. BSIs 83 
can be caused by various microorganisms. In the absence of microbiological documentation, a BSI is 84 
suspected by the physicians on the basis of clinical symptoms, which trigger the start of empirical 85 
treatments. The clinical presentations are multiple and include: fever or hypothermia, increases in heart 86 
rate, change in inflammatory variable (C-reactive protein, procalcitonin and white blood cell count 87 
increase), organ failure (58; 178). These symptoms are generally non specific and only suggest 88 
bloodstream dissemination. Empirical treatments are made of broad spectrum antibiotics on the basis of 89 
the clinical and epidemiological data, but this does not exclude any risk of inappropriate initial treatment. 90 
Similar to delayed introduction of the first antibiotic treatment, an inadequate treatment is associated with 91 
a significant increase of mortality (188; 265). In a recent study there was a nearly 3-fold increase in the 92 
risk of mortality when the antimicrobial treatment was inappropriate (28). Pseudomonas aeruginosa or 93 
Acinetobacter baumannii that are associated with frequent multi-drug resistant profile are often the 94 
microorganisms for which empirical antibiotic coverage are inappropriate. Enterobacteriaceae producing 95 
Extended Spectrum Beta-Lactamase (ESBL) such as Escherichia coli or producing inducible 96 
cephalosporinase such as Enterobacter cloacae, are also commonly associated with an inadequate 97 
empirical treatment (37). The mortality rate of patient suffering of a methicillin resistant Staphylococcus 98 
aureus (MRSA)-associated BSI was significantly higher among patients receiving an inappropriate 99 
empirical antibiotic treatment (168/342, 49.1%) than among patients receiving an appropriate empirical 100 
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antibiotic treatment (56/168, 33.3%) (92; 187). Inadequate treatments can also occur for organisms such 101 
as Enterococcus faecalis species that are intrinsically resistant to some commonly administered first-line 102 
antibiotics such as Ceftriaxone (265). Broad-spectrum molecules also have a detrimental impact on 103 
beneficial bacteria that constitute the protective flora and contribute to the emergence of multi-drug 104 
resistant strains. Moreover, some of these antimicrobial molecules can also have a toxic effect for the 105 
patient (144; 188; 265). The rapid identification of the causative agent of the BSI thus allows the 106 
adjustment of the anti-infectious therapy or the reduction of the spectrum (de-escalation) with significant 107 
clinical benefits. 108 
BSIs are characterized by a low quantity of circulating microbes. On the basis of plating methods, the 109 
bacterial load has been estimated to be around 1 to 10 CFU per ml of blood in adults (105; 132; 133; 243; 110 
251). This method is efficient to determine the amount of bacteria that survived the plating protocol; 111 
hence the true number of circulating bacteria is likely underestimated. DNA copies present in the 112 
circulation should be even higher as it also includes DNA released by dead bacteria or clumping bacteria 113 
as well as DNA from bacteria engulfed in phagocytes. On the basis of quantitative PCR, Bacconi et al. 114 
have recently estimated that during bacteremia, the blood contains 103 to 104 bacterial cells per ml (13), 115 
which is higher than the analytic sensitivity of most of the available molecular methods. 116 
Hence, the ideal diagnostic method for BSI should be: 1) able to identify a broad range of pathogen, 2) 117 
have an analytic sensitivity lower than 10-100 CFU/ml, 3) rapid, 4) quantitative to give an idea of the 118 
severity of the infection, 5) give an antibiotic susceptibility profile, 6) associated with low hands-on time 119 
and 7) automated (65). These are all potential characteristics that molecular diagnosis methods may fulfil, 120 
at least to some extent. 121 
Molecular methods for the diagnosis of BSI refer to nucleic acid-based methods but also to non-nucleic 122 
acid-based.  PCR based methods that constitute the nucleic acid amplification-based methods can be 123 
applied both on positive blood culture and on whole blood. Indeed the PCR step increases the sensitivity 124 
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of the detection which makes it suitable for paucibacterial samples such as blood (Figure 1)(174). 125 
Nucleic-acid based methods non amplification based such as FISH (fluorescent n situ hybridization) or 126 
microarray have limited sensitivity. Hence, they are restricted to positive blood-culture. For the same 127 
reason, MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass 128 
Spectrometry) a non-nucleic acid based method that analyse microbial protein mass-spectrum is suitable 129 
for diagnosis from positive blood-culture. 130 
In this chapter we will present the molecular methods available for the microbial diagnosis of BSI. We 131 
will report and discuss the performance as well as the advantages and the inconvenient of these methods. 132 
2. Blood culture-based diagnosis of bloodstream infections 133 
Blood culture (BC) is currently the gold standard to establish the etiology of bloodstream infection. Blood 134 
bottles contain specific liquid broth for growth of bacteria or fungi present in blood. Distinct media are 135 
available to grow different microbes (174). BC-based diagnosis has been improved by the use automated 136 
incubators that can detect bacterial or fungal growth into blood bottles thanks to associated 137 
physicochemical variations. When the automated system detects the growth, visualisation of the 138 
microorganism is possible using standard Gram or fluorescent staining (figure 2). The Gram staining can 139 
give a first presumptive etiology of the BSI. However, only the final identification of the pathogen and its 140 
antibiotic susceptibility testing can insure the adequacy of the ongoing antibiotic treatment. Thus, when a 141 
blood culture is detected as positive, diagnostic laboratories have to identify the microbe rapidly and with 142 
the highest sensitivity and specificity. However, the time to positivity (TTP) of the blood-culture bottles 143 
can vary from few hours to 24-48 hours for fast growing bacteria, and even more for slow growing 144 
bacteria or fungi. In addition, it is generally admitted that more than 50% of BSI occur with negative 145 
blood culture (57; 79). When the blood culture become positive, using conventional methods, one or more 146 
days can be necessary to identify the pathogen and to determine the exact etiology of the BSI (figure 2). 147 
These methods include phenotypic characterisation using biochemical and enzymatic tests. Most of these 148 
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phenotypic characterizations require a subculture in liquid media or a subculture on solid media to obtain 149 
isolated colonies.  Finally, BSI involving multiple organisms may also further increase the time to 150 
identification of most detection methods. 151 
Inside positive BC, bacteria concentration reaches 1.106 to 2.108 for gram-negative cocci and 2.107 to 152 
1.109 for gram-negative bacilli (42; 229). These concentrations allow the use of amplification-based 153 
methods such as PCR and real-time PCR as well as non amplification-based methods such hybridization 154 
or MALDI-TOF MS (figure 1).       155 
Blood is a challenging sample for the detection and the identification of pathogens since it contains a low 156 
number of microorganisms in comparison to human components (DNA, proteins and cells) (175). These 157 
compounds can interfere with the detection or identification by leading to false positive or false negative 158 
(inhibition). All these components are transferred into the blood culture at time of the blood sampling. 159 
MALDI-TOF MS is a non-nucleic acid based molecular methods that has considerably accelerated and 160 
simplified the identification of pathogen from positive culture. MALDI-TOF MS is based on the analysis 161 
of the mass spectrum generated by bacterial proteins, mainly house-keeping proteins (figure 3). This 162 
technique is now applicable on positive blood culture but still requires a sample preparation step to 163 
discard blood and other non-bacterial components.  164 
3. Microbial diagnosis of bloodstream infections directly from blood 165 
The diagnostic of BSI directly from whole blood has been a major concern for medical diagnostic 166 
microbiologists. Indeed blood cultures appear to have some intrinsic limitations: 1) approximately fifty 167 
percent of BSI are BC negative (57; 79) and 2) in the case of positive BC, the TTP can vary from hours to 168 
days 3) BC requires a high quantity of blood that is difficult to obtain from some patients such as 169 
pediatric patients 4) an antibiotic treatment is often initiated prior to blood culture. Many technical 170 
improvements have been made to increase the performance of detection methods from whole blood but 171 
some limitations remained. Nucleic-acid based methods were limited by the need of large volume of 172 
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blood due to the low number of CFU per ml associated with the presence of human DNA in excess 173 
mainly due to white blood cells DNA (4). In addition, these methods are also sensitive to contaminant - 174 
bacterial or fungal DNA – or to the presence of DNA from dead organisms that could lead to false 175 
positive results (21; 162; 237; 238). Quantitative analyses are more powerful to interpret such positive 176 
results.  177 
To improve the sensitivity of or nucleic acid based methods, the excess of human DNA should be 178 
removed. This could be achieved by removing white blood cells before nucleic acid extraction or by 179 
selective removal of human DNA after extraction. Nucleic acid based methods, in particular PCR, are 180 
sensitive to various inhibition mechanisms. Some of these mechanisms have been characterized but many 181 
of them remain unknown (112; 175; 195; 259). Inhibitory compounds can be contained in the sample or 182 
they can be the result of the sample preparation process. The blood contains some well known PCR 183 
inhibitors such as haemoglobin, bile salts and heme found in erythrocytes (2; 4; 111) as well as in 184 
lactoferrin found in leukocytes (4). The inhibition of PCR-based methods by these compounds is due to 185 
the release of iron (from heme)  that is known to interfere with DNA synthesis (27). Immunoglobulin 186 
present in the bloodstream in particular IgG can inhibit PCR by binding single stranded DNA (3). Red 187 
blood cells present in blood bottles can also impair non-nucleic acid based methods such as MALDI-TOF 188 
MS as they bring a high amount of proteins that would interfere with the quality of the protein mass 189 
spectrum. Several protocols are now available for their removal prior MALDI-TOF MS analysis from 190 
positive blood bottles (51; 174; 253). 191 
At present, each available molecular method is associated with a specific sample preparation. For the 192 
detection of a large number of organisms, the limited sensitivity of broad-range PCR targeting house-193 
keeping genes have been overcame by the use of multiplex PCR or multiple real-time PCR. A recent 194 
technology, PCR/ESI-MS (PCR and Electrospray Ionization Mass Spectrometry) is a method that 195 
associates PCR and ESI-MS. The PCR allows the specific detection of low amount of bacterial, fungal or 196 
viral DNA from whole blood. This technology is associated with the analysis of PCR amplicon by ESI-197 
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MS that determine the base composition rather than the nucleotide sequence. This has been shown to be 198 
sufficient for organism identification at the species level. Methods are now developed to remove the 199 
excess of non bacterial DNA and or inhibitors (4; 195; 202; 259).  Most of these methods are time 200 
consuming, require intensive labour and are specific for one type of sample, one type of analysis or one 201 
type of device. 202 
MOLECULAR METHODS FOR THE IDENTIFICATION OF PATHOGEN 203 
FROM POSITIVE BLOOD CULTURES  204 
BC is currently the reference method for the identification of pathogens involved in BSI because it is easy 205 
to perform and sensitive due to the large volume of blood that could be analysed when multiple blood 206 
bottles are collected (174). When a BC is positive, conventional methods including phenotypic 207 
characterisation and rRNA gene sequencing have an extremely high specificity. However these methods 208 
are time consuming because they require an additional subculture and are challenged by a broad variety of 209 
molecular methods. Fluorescent in situ hybridization (FISH), the first molecular method that has been 210 
developed, is based on the binding of specific probes on pathogens DNA. FISH is a rapid, sensitive and 211 
specific method but is dependent on the choice of the probes to be tested. Microarrays allowed the 212 
detection and identification of pathogens as well as resistance genes. PCR-based methods allow the rapid 213 
detection of a single organism (specific real-time PCR) or multiple organisms (broad-range PCR or 214 
multiplex PCR). These methods are highly sensitive to contaminating DNA or PCR inhibitors.  MALDI-215 
TOF MS, one of the latest commercialized technologies is presented as a revolution for clinical 216 
microbiology laboratories (18). Indeed, MALDI-TOF MS may identify in less than one our most bacterial 217 
and fungal agents generally recovered from BCs. 218 
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1. Fluorescent in situ hybridization (FISH)  219 
Fluorescent in situ hybridization (FISH) is based on the specific binding of fluorescent peptide nucleic 220 
acid probes (PNA) to the rRNA – 16S rRNA for bacteria and 18S rRNA for fungi and other eukaryotes. 221 
Basically, slides are prepared from a positive blood culture, the fluorescent PNA are applied and unbound 222 
PNA are removed by a washing step. Bound fluorescent PNA is generally observed using a fluorescent 223 
microscope as flow cytometry detection still need further investigation and development (11). FISH 224 
requires a high number of living cells which prevent its use directly on whole blood. Multiples probes that 225 
recognize microorganisms at the genus level or at the species level are available. All the solutions are 226 
based on multiple probes that detect and distinguish two or three organisms. A first kit of the PNA-FISH 227 
system (AdvanDx, Wolburn, MA) allowed the detection of S. aureus and coagulase negative 228 
staphylococci (36; 86; 93; 104; 173). A second kit allows the detection of Enterococcus faecalis versus 229 
Enterococcus faecium and other Enterococcus spp. (OE) (87). E. coli and P. aeruginosa can be detected 230 
using a PNA mix or using a mix of three probes that include also K. pneumoniae (183; 189; 220). C. 231 
albicans, C. glabrata, C. parapsilosis and C. krusei can also be detected (74; 100; 199; 215; 255). 232 
The Quick-FISH system is a more rapid version of the PNA-FISH system. The turnaround time (TAT) is 233 
shortened by reducing the hybridization phases to 15 min and by removing the wash step. At present, the 234 
QuickFISH system provides kits that detect and distinguish S. aureus/Coagulase negative staphylococci, 235 
Enterococcus faecalis/Enterococcus faecium, E. coli/P. aeruginosa (55; 56; 158). The diversity of 236 
microorganisms that is currently detected is still limited but these bacterial species represent about 95% of 237 
the pathogen involved in BSI. The choice of the probe to be tested will depend on the Gram result, the 238 
clinical presentation and the local epidemiology. The sensitivity of the QuickFISH system is 99.5% for 239 
the detection of S. aureus and 98.8% for coagulase negative staphylococci, with a combined specificity of 240 
89.5% (55). Martinez et al. reported 97.9% of concordance with conventional detection methods for 241 
Gram-positive bacteria and 95.7% for gram-negative bacteria (158). Yeast (C. albicans, C. parapsilosis, 242 
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C. tropicalis, C. glabrata and C. krusei) can also be identified using probes targeting 26S rRNA 243 
sequences (74). Commercial methods give a result in 1.5 to 3 hours with high sensitivity and specificity, 244 
but could not replace other detection methods as many significant pathogens are not detected using these 245 
probes (table 2) (31; 87; 158; 242). 246 
2. Microarray 247 
Microarrays are based on species-specific or genus-specific DNA probes immobilized on chip on which 248 
microorganisms DNA will specifically hybridize. The high-density of the chips allow the use of 249 
sequences specific for different pathogens and probes for the detection of virulence factors and/or 250 
resistance genes. Species identification is determined by the pattern of hybridization and on the intensity 251 
of the signal (47; 179; 254; 264). The analytic sensitivity of microarrays ranges between 10 to 105 252 
CFU/ml depending on the pathogen, which allows their use from positive BC but not directly from blood 253 
(254). The Verigene Gram-Positive Blood Culture system and the Verigene gram-negative Blood Culture 254 
system (Northbrook, IL, USA) can detect gram-negative or gram-negative microorganisms respectively, 255 
as well as associated resistance genes. The time to identification is approximately 2.5 h from positive 256 
blood culture bottles (table 2). After being extracted from 350 μl  of blood culture from positive vial, the 257 
bacterial DNA is suspended in a specific buffer and hybridized on specific synthetic oligonucleotides 258 
followed by a second hybridization step involve gold particles. The signal is further amplified via a silver 259 
staining process which increases the sensitivity of the system. The reading is automated. The Verigene 260 
Gram-Positive Blood Culture system can detect 9 organisms at the species level (Staphylococcus aureus, 261 
Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus anginosus group, Streptococcus 262 
agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus 263 
faecium), 4 genus (Staphylococcus spp, Streptococcus spp., Micrococcus spp. and Listeria spp.) and 264 
detect 3 resistance genes (mecA (methicillin), vanA (vancomycin) and vanB (vancomycin).  Studies 265 
performed on both adult and pediatric patients reported 89.7% to 99% of concordance for the detection 266 
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from positive BC between the Verigene Gram-Positive Blood Culture system and the traditional method 267 
(5; 14; 158; 165; 206; 227; 258). Misidentifications have been reported for Streptococcus spp.. In 268 
particular group mitis Streptococcus spp. have been misidentified with S. pneumoniae and S. oralis have 269 
been misidentified with S. anginosus (206). Performances of the Verigene system are higher on mono-270 
bacterial samples. Mixed culture can prevent the identification of one of the pathogen. Buchan et al 271 
reported 98.6% of sensitivity and 94.3% of specificity for the detection of the mecA gene in 5999 272 
Staphylococci cultures, and 100% of sensitivity and specificity for the detection the vanA gene in 81 273 
cultures containing Enterococcus faecalis and Enterococcus faecium (26). Samuel et al reported 91% of 274 
concordance for mecA and 100% for vanA detection when compared to routine methods (206). In case of 275 
mixed population of staphylococci, the resistance gene cannot be associated to a specific pathogen (26). 276 
The Verigene Gram-Negative can detect 5 pathogens at the species level (Escherichia coli, Klebsiella 277 
pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa and Serratia marcescens) and 4 genus 278 
(Acinetobacter spp., Citrobacter spp., Enterobacter spp. and Proteus spp.). The Verigene Gram Negative 279 
BC assay displays 91 to 100% of agreement for the detection of gram negative pathogens both from adult 280 
and pediatric patients (17; 60; 108; 155; 226). Among, the false-negative results, mixed blood cultures 281 
have been incriminated; but some of these negative or non called results involved bacteria covered by the 282 
chip (60). As for many molecular assays, it is not possible to distinguish E. coli and Shigella spp. (S. 283 
dysenteriae, S. flexneri, S. boydii, and S. sonnei). This distinction should be achieved with enzymatic 284 
analysis. The Verigene Gram Negative assay can detect 6 resistance genes: the extended-spectrum beta-285 
lactamase (ESBL) CTX-M and the carbapenemases KPC, NDM, VIM, IMP and OXA groups with 92.3% 286 
to 100% of concordance with routine methods (60; 234). Other microarrays for the detection of resistance 287 
gene are currently being developed (24).  288 
The performances of microarrays are extremely high for both the detection of pathogen and resistance 289 
cassettes when applied to positive blood cultures but supported by a limited number of studies. 290 
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3. Nucleic acid amplification-based methods 291 
PCR provide a rapid and specific technology for pathogen identification from positive BC (260). The 292 
specificity provided initially by the use of specific primers can be increased in the case of real time PCR, 293 
by the use of specific probes. The use of PCR on blood or on hemorrhagic samples, was limited for long-294 
time by the fact that PCR is sensitive to the presence of inhibitory compounds such as haemoglobin 295 
contained in erythrocytes (2; 4; 111),  lactoferrin contained in leukocytes (4), or immunoglobulin  (3). To 296 
avoid inhibition, recent methods use new or improved nucleic acid extraction and/or amplification 297 
techniques.   298 
Multiplex-PCR increases the time to result as it interrogates several targets (pathogens or resistance 299 
genes) at the same time. In addition it can increase both the specificity and the sensitivity of an analysis 300 
thanks to the use of multiple targets for the same organism (120; 223). Multiplexing is achieved through 301 
the use of several specific primers pairs in the same reaction. Different methods can be applied to identify 302 
the amplified sequence(s): 1) the use of specific probes labelled with distinct fluorochromes, 2) the 303 
analysis of the probe or the amplicon melting curves (69; 72; 257); 3) the amplicon size (electrophoreses); 304 
4) the sequencing of the amplification product. The latest technology, PCR/ESI-MS, is based on the 305 
analysis of the amplicon by MS (Figure 5). The latter technique will be discussed in depth in the 306 
paragraph on pathogen detection from blood.    307 
Multiplex PCR 308 
The FilmArray system (Idaho Technology, Salt Lake City, UT, USA) using multiple-PCR is a solution 309 
that allows the identification of more than 25 pathogens and 4 antibiotic resistance genes from positive 310 
BC in 1 h (19). The FilmArray is a closed system that uses multiple-PCR expected to identify 90 to 95% 311 
of the pathogens involved in BSI as well as the resistance genes mecA, vanA and vanB and blaKPC . A kit 312 
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for the identification of potential bioterrorism agent (Bacillus anthracis, Francisella tularensis and 313 
Yersinia pestis) is also available (249).  314 
In a prospective study on 102 blood cultures, the FilmArray system displayed 91% of sensitivity and 77% 315 
of specificity when compared to conventional identification methods for the detection of pathogen present 316 
in the FilmArray panel only (19). The detection of resistance genes revealed 100% of specificity and 317 
100% of sensitivity in this study. In another study, FilmArray displayed 98.5% of sensitivity and 100% of 318 
specificity for the identification of gram-negative bacteria, 96.7% of sensitivity and 93.7% of specificity 319 
form gram-negative bacteria and 96% of sensitivity and 98.9% of specificity for the detection of the mecA 320 
gene. Another study performed on 118 mono-bacterial culture reported 92% of correct identification of 321 
the FilmArray system, but mixed cultures gave no results (17). The identification of Candida albicans 322 
and Candida glabrata reached 100% of sensitivity and 99.5% of specificity (6). This is consistent with 323 
other study showing high performance of the FilmArray for the identification C. albicans and C. glabrata 324 
(181).  The FilmArray can also be applied  on other sterile samples such as  CSF (184).  325 
Rapid PCR-based systems  326 
The clinical and epidemiological impact of pathogens such as methicillin resistant Staphylococcus aureus 327 
(MRSA) or rifampicin resistance Mycobacterium tuberculosis has contributed to the development of 328 
methods for the rapid detection of resistance. S. aureus is a significant agent of community-acquired and 329 
nosocomial infections (256). The mortality rate is increased in patient infected with MRSA in comparison 330 
to patient infected with MSSA (methicillin sensitive S. aureus) (49; 50; 263). The increased percentage of 331 
MRSA in comparison to MSSA has stressed the importance of rapid detections methods of MRSA (71; 332 
77; 169; 170). Several methods based on multiplex real-time PCR are available: the GeneXpert 333 
MRSA/SA BC Assay (Cepheid, Sunnyvale, CA) (45; 221), the StaphSR assay (BD GeneOhm, San 334 
Diego, CA) (117; 222) and the StaphPlex (Genaco Biomedical Products, Huntsville, AL, USA) (230). 335 
The GeneXpert and StaphSR assay are rapid PCR-based systems developed for the detection of S. aureus 336 
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only in approximately 1.5 h. They require only limited hands-on time and skills. The application of the 337 
GeneXpert MRSA on positive blood culture was shown to have an impact on anti-infectious treatments 338 
by reducing the use of glycopeptides (46). Alternatively, the StaphPlex system can identify several 339 
staphylococci at the species level. The StaphPlex system is based on several PCRs (18 target genes) and 340 
microarray analysis for the identification of staphylococci at the species-level, the detection of resistance 341 
genes and of the Panton-Valentine leukocidin (PVL). The results are obtained within 5 hours (230). 342 
Because these methods are largely aimed to detect resistance genes, they will be presented and discussed 343 
in the chapter dedicated to resistance detection. 344 
4. Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass 345 
Spectrometry (MALDI-TOF MS) 346 
Principle of MALDI-TOF MS  347 
The MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry) 348 
is a method that allows identification of a broad range of microbes at the species or at the genus level 349 
from positive culture. The method was first developed to be used on colonies before its application on 350 
BC. Microbe identification using MALDI-TOF MS is based on the analysis of the mass spectrum 351 
generated by bacterial or fungal component, mainly house-keeping proteins (the ribosomal proteins which 352 
are basic are specifically extracted using acidic matrix).  This spectrum is a unique fingerprint for each 353 
microorganism but displays features shared between genetically related bacteria (44). The comparison of 354 
the spectrum with a database of spectrum obtained for characterized organisms allow microbes 355 
identification at the species or at the genus level depending of a score assigned by the identification 356 
software (52). 357 
MALDI-TOF MS was first used for bacterial identification in 1975 (8).  The routine use of mass 358 
spectrometry in diagnostic laboratory for the identification of bacteria was proposed in 1996 when correct 359 
17 
 
identification has been achieved directly from whole bacteria coming from single colonies (44; 110).  360 
Identification of bacteria using the MALDI-TOF MS is divided in three steps: (1) ionization of the 361 
sample, (2) separation of proteins in a flight tube (3) generation of a mass spectrum by determination of 362 
the mass of the proteins (figure 3). The sample preparation consists in mixing the cells from a bacterial 363 
colony, with a crystallizing matrix that will trigger the ionization of the sample achieved by a laser 364 
(MALDI). Protein accessibility can be facilitated by a quick formic acid extraction.  Ionized proteins are 365 
accelerated by an electrostatic field and separated along a flight tube. The separation is due to the time of 366 
flight (TOF), a function of the mass and of the charge of the proteins. Protein detections will generate a 367 
mass spectrum unique for a defined bacterial strain corresponding to mass-to-charge ratio (m/z) between 368 
1000 and 20000 kDa. However, several peaks are shared between bacteria from the same genus or species 369 
and serve as biomarkers for bacterial identification. The identification is performed by comparison of the 370 
mass spectrum with a database of spectra obtained from characterized bacterial strains. The software that 371 
performed the spectral analysis and the comparison with the database, assign a score for the identification. 372 
Depending on the threshold recommended by the furnisher and the in-house algorithm, the identification 373 
can be rejected, or accepted either at the species level or only at the genus level.    374 
Application of MALDI-TOF MS on positive blood culture bottle 375 
In clinical microbiology, the MALDI-TOF MS was first used on pure bacterial colonies before its 376 
application on positive BC for the diagnostic of BSI (figure 3) (52). The initial analysis on a positive 377 
blood culture bottle is a Gram staining. The Gram staining is especially recommended 1) to confirm that 378 
the detection is truly due to the presence of a microorganism and 2) give a presumptive etiology of the 379 
BSI and 3) to disclose mixed bacteremia.  In positive blood cultures, the bacterial concentration is ranging 380 
from 106 to 109 CFU/ml, which in theory is sufficient for MALDI-TOF MS identification. However, the 381 
presence of high amount of non bacterial material (erythrocytes, nutrient from the growth media) impairs 382 
the direct identification from the blood vial. 383 
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Application of MALDI-TOF MS after a short subculture  384 
A short subculture (2 to 3 hours) on agar plates can be performed from the positive blood vial to obtain a 385 
thin layer of bacteria (174). From this thin layer, the MALDI-TOF MS analysis can be performed (figure 386 
2) (116; 239). Short subcultures are also adequate for AST using automated systems (116).  However, this 387 
procedure is mainly suitable for fast growing bacteria.  388 
Application of MALDI-TOF MS directly from the blood culture vial via a bacterial pellet 389 
The fasted method is to perform the identification directly from the positive BC (figure 2 and figure 3). 390 
The goal is to get rid of non bacterial components present in the bottles such as red blood cells and to 391 
concentrate the bacteria. Bacterial concentration can be achieved by centrifugation and erythrocyte lysis 392 
by ammonium chloride (51; 193). This generates a pellet that can be identified by MALDI-TOF MS 393 
(figure 3). This method allowed the identification of 78.7% of the samples obtained. Moreover, 99% of 394 
the MALDI-TOF MS identifications were correct at the species level (193). Alternative erythrocytes lysis 395 
techniques can be achieved with formic acid (136). Any methods implying mild detergent that would 396 
solubilise erythrocytes membrane but not microbe membrane lead to similar results (83; 163; 168). 397 
Alternatively, gel-based separator tubes have proven efficiency in concentrating bacteria and removing 398 
red blood cells (224). 399 
MALDI-TOF MS has a major impact on the time to result since it can be achieved directly from positive 400 
blood culture, without subculture (61). The sample processing  and identification using MALDI-TOF MS 401 
takes approximately 1 hour, which makes it time effective for fast growing bacteria as well (136; 193). 402 
The accuracy of the MALDI-TOF MS identification is dependent on extended and correct spectrum 403 
database. This database can be implemented with spectrum obtained from clinical isolates. This is 404 
applicable for strains for which the MS identification failed and that were identified without any doubt 405 
with other methods such as gene sequencing or enzymatic assay. This is also applicable for rare 406 
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pathogens that can be identified faster and accurately using MALDI-TOF MS (176; 213). However, some 407 
closely related bacterial species such as the different Streptococcus species remain difficult to distinguish 408 
using MALDI-TOF MS. For instance, group mitis Streptococcus are often misidentified as S. 409 
pneumoniae. S. pneumoniae identification should thus be confirmed by phenotypic test such as optochine 410 
susceptibility (126; 224; 227). Similarly, the distinction of E. coli and Shigella sp. is impossible using 411 
routine MALDI-TOF MS procedures and requires additional phenotypic confirmation (59; 210). 412 
Recently, a new approach based on the analysis of biomarker peaks has been proposed to differentiate 413 
these two closely related pathogens (128). 414 
Efficiency and reproducibility of MALDI-TOF MS identification 415 
Even if a mass spectrum can be obtained from a single colony, this biomass represents a significant 416 
amount of bacteria. MALDI-TOF MS identification is therefore not applicable directly from blood but is 417 
dependent on microorganisms proliferation in BC and on an additional concentration step from the 418 
positive BC (174). The requirement of a culture limits the use of the MALDI-TOF for the detection of 419 
non-cultivable bacteria. 420 
Proteins used as biomarkers for MALDI-TOF MS identification of bacteria are mainly involved in house-421 
keeping functions (246). Ribosomal proteins contribute to approximately half of the peaks present in the 422 
mass spectrum (10; 201).  This makes it reproducible and robust as several peaks would be conserved in 423 
genetically related bacteria. Nevertheless, experimental conditions can impact the presence and the 424 
relative abundance of detected peaks. This is true for both routine identification or for the implementation 425 
of the peaks pattern into the in-house database. The culture media, the growth conditions and the age of 426 
the colony may impact the spectrum (235). The presence of agar residue or blood proteins in the sample 427 
may impact the spectrum quality (52).  Quality of the matrix may also influence the spectrum (246).  428 
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Importance of the Gram staining and of the subculture 429 
The Gram staining on positive blood culture is still mandatory (i) to confirm the presence of a microbe in 430 
the bottles (ii) to validate the identification of the MALDI-TOF MS, which should be congruent with the 431 
characteristic provided by the Gram (88) (iii) to disclose polymicrobial infections as the MALDI-TOF 432 
MS poorly identify mixed bacterial samples. Mixed infection may also be detected upon subculture, 433 
which also remains essential for the antimicrobial susceptibility testing (see later). 434 
  435 
MOLECULAR METHODS FOR THE DETECTION OF PATHOGENS 436 
DIRECTLY FROM BLOOD 437 
BSI is initially suspected by clinicians on the basis of clinical signs and symptoms. At this stage the 438 
etiological agent is however difficult to suspect as the clinical presentation is generally similar. To 439 
accelerate the time to result of microbial diagnosis, molecular methods that can be used directly on whole 440 
blood have been proposed. Nevertheless, blood as sample presented many technical limitations: 1) the 441 
low quantity of circulating microbes during BSI (1 to 10 CFU per ml), 2) the presence of PCR inhibitor in 442 
blood that are not completely removed by current nucleic acid extraction methods (see Introduction 443 
section), 3)  the sensitivity of  PCR to contamination; which implies the use of highly pure (nucleic acid 444 
free) material and ideally to perform quantitative analyses (211), 4) the ability of  PCRs to detect the 445 
presence of  DNA from both living and dead microbes which makes the interpretation of positive results 446 
difficult (BSI versus DNAemia and 5) the presence of human DNA in excess . 447 
Different PCR technologies are now available. Broad-range PCRs could be useful, especially when the 448 
etiological agent cannot be suspected, but they are often limited by lower sensitivity. Pathogen specific 449 
PCRs display higher sensitivity.  Real-time PCRs can be multiplexed to detect several targets at the same 450 
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time with a good sensitivity. A recent innovation that can also be use directly on whole blood is PCR-451 
ESI-MS that is presented as a universal and fast method. 452 
1. Broad range PCR 453 
The need for a PCR-based universal detection method is stressed by the importance of rapid diagnostic in 454 
the setting of critically-ill patients, especially since the etiology of the BSI is difficult to establish on the 455 
basis of the clinical presentations. This is the case for neonate patients with the additional difficulty that 456 
only small volumes of blood are available, which decreases significantly the sensitivity of BC. 457 
Alternatively, such universal and sensitive methods may be used to screen blood samples taken from 458 
neutropenic patients or other high risk subjects to early detect the etiological agent of a BSI.  459 
The 16S rRNA gene that displays sufficient level of conservation among bacterial species is the target of 460 
in-house PCRs used in many molecular diagnostic laboratories (12; 40; 41; 43; 94). In many organisms, 461 
the ribosomal operon is present in multiple copies which increases the sensitivity of PCRs targeting this 462 
genomic region. The intergenic spacer is more polymorphic and more species specific.  Specific PCR 463 
primers are designed on conserved regions that surround highly variable region. Thus, the sequencing of 464 
the amplicon allows the identification of the microbe at the genius or at species level. Most of these PCR 465 
cannot be used directly on blood because of their limited sensitivity and specificity. However, some 466 
studies have reported sensitivity of PCR targeting the 16S rRNA gene ranging from 10 to 2.5.102 CFU 467 
per reaction directly from blood (131; 191). Gaibani et al have developed a broad-range real-time PCR 468 
that targets a 97 base pair sequence of the 23S rRNA gene. This PCR is expected to detect 90% of the 469 
bacteria involved in BSI but does not give any identification, since the short fragments amplified do not 470 
allow discrimination upon sequencing (89). This real-time PCR can be used on whole blood (100 μl). Its 471 
sensitivity is ranging from 10 to 103 CFU per reactions for E. coli and S. aureus, depending on the 472 
extraction method.  473 
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The SepsiTest system (Molzym, Bremen, Germany) is based on broad-range PCR using universal primers 474 
that target the 16S rRNA gene for bacterial identification and the 18S rRNA for fungal identification. The 475 
amplicon are sequenced and analysed by BLAST to give identification at the species level (=> 99% of 476 
identity) or genus level (=> 97%) (134; 250). Of course this cut-off does not apply to all bacterial species 477 
and should be used with caution. The analysis is achieved from 1ml of whole blood. After lysis of human 478 
cells, the human DNA is degraded by a DNAse. The PCR is achieved using reagent provided by the 479 
manufacturer and lead to amplicon of about 450 base pairs. The time to result is approximately 6 hours. 480 
Depending on the study, the sensitivity and specificity are variable when compared to BC. A first study 481 
performed in critically-ill patients led to 28.6% of sensitivity and 85.3% of specificity of the SepsiTest 482 
when BC is used as gold standard (145; 212). In a second study, pathogen could be detected in 26 % 483 
(13/50) of the critically-ill patients while SepsiTest could detect pathogens in only 12 % of the patients 484 
(212).  In a third study, still using BC as gold standard, SepsiTest sensitivity was 21% and specificity was 485 
96% (152). In contrast, high sensitivity and acceptable specificity (87% and 85.5%) was monitored in a 486 
multicenter study involving 342 blood samples from 187 patients (250). In a study performed on patients 487 
supported by extracorporeal membrane oxygenation, the sensitivity and specificity were 78.6 % and 88.4 488 
% when compared to BC with 97.7% of concordance of positive results (177; 200). In this study, 489 
SepsiTest could detect at least a pathogen in 25% of patients with negative BC. For patient with suspected 490 
endocarditis, Kuhn et al. reported higher performances of SepsiTest over BC (134). The variable 491 
sensitivity and specificity of the SepsiTest when compared to BC needs to be investigated.  One specific 492 
feature of SepsiTest is that it can be used on sterile samples other than blood with the potential to replace 493 
home-made broad-range PCR (96; 200). A limitation of this method is that the extraction is not automated 494 
(99). Another important limitation of all these molecular tests is that they do not provide strain for 495 
detailed antibiotic susceptibility testing.  496 
The VYOO system (SIRS-Lab, Jena, Germany) is based on multiplex PCRs that can detect 34 bacteria 497 
and 7 fungi from 5 ml of whole blood. The system contains several steps, including non-automated steps. 498 
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Nucleic acid extraction is assisted by magnetic beads. Then there is a step of enrichment in microbial 499 
DNA based on i) the methylation difference between microbes (bacteria and fungi) DNA and the human 500 
DNA and ii) the use of chromatography affinity (202). The PCR is achieved on DNA which concentration 501 
has to be manually adjusted to 1 μg in 25ul. Two PCRs with a specific pool of primers are required. The 502 
amplicons are applied to an electrophoresis in an ethidium bromide stained agarose gel. Pathogen 503 
identification is determined on the basis of the band pattern. 504 
In a study performed on 311 blood samples from 245 patients of an ICU of a university hospital analysed 505 
in parallel with BC and with the VYOO system, the VYOO system gave 30.1% of positive samples, with 506 
a median time to result of 24.2 hours and BC bottle gave 14.5% of positive samples with a median time to 507 
positivity of 68 hours with only 40% of correlation between the two methods (22). PCR positive samples 508 
correlated well with the level of procalcitonin. Additionally the PCR results from blood were most of the 509 
time confirmed by the pathogen identified in the suspected site of infection.  Importantly 34% of the 510 
patients with positive VYOO test, the anti-infectious therapy was inadequate, including infections that 511 
involved VRE, multi-drug resistant staphylococci and fungi (22). In another study, the VYOO gave 512 
positive results in 51.4% of samples from patient with BSI, when BC gave 27.7% of positive results (84).  513 
These studies suggest that VYOO is more sensitive than BC, which could be explained by the association 514 
of a large starting volume (5 ml) and the enrichment in microbial DNA before amplification. More studies 515 
are required but these preliminary performances are promising despite the fact that many steps are not yet 516 
automated and that. 517 
2. Real-time PCR and Multiplex PCR 518 
 519 
The multiplexing of real-time PCRs allows detecting simultaneously several microbes with a good 520 
sensitivity and specificity. This is the technology used for the LightCycler SeptiFast system (Roche 521 
Molecular System, Germany), the MagicPlex Sepsis system (Seegene, Seoul, Korea). 522 
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Principle of the LightCycler SeptiFast system 523 
The LightCycler SeptiFast system is based on broad-range real-time PCR that can identify 19 pathogens 524 
(8 gram-negative bacteria, 6 gram-negative bacteria and 5 fungi) representing approximately 90% of the 525 
pathogen responsible for BSI. The SeptiFast can be used directly from whole blood with an overall time 526 
to result of about 5 hours (3.5 when associated to an automated extraction system). The targets of the 527 
multiplexed broad-range real-time PCR are the internal transcribed spacer (ITS) between the 16S and the 528 
23S ribosomal DNA for bacteria and the ITS between the 18S and the 5.8S ribosomal DNA for fungi. 529 
Identification at the species level is determined by the distinct melting curves of the specific probes. The 530 
LightCycler can detect 8 gram-negative bacteria detected: E. coli, Klebsiella pneumonia/ Klebsiella 531 
oxytoca, Enterobacter cloacae/ Enterobacter aerogenes species, Proteus mirabilis, Pseudomonas 532 
aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia. Six Gram-positive bacteria can be 533 
recognized: S. aureus, coagulase negative staphylococci, Streptococcus pneumoniae, Streptococcus 534 
pyogenes, Streptococcus agalactiae / Streptococcus mitis, Enterococcus faecium and Enterococcus 535 
faecalis. Six fungi can be detected and identified at the species level: Candida albicans, Candida 536 
tropicalis, Candida parapsilosis, Candida glabrata, Candida krusei and Aspergillus fumigatus. Basically, 537 
the assay consists of three separated reactions that contain distinct primers and probes mixes to detect 538 
respectively gram-negative bacteria, gram-negative bacteria and fungi. The LightCycler SeptiFast is 539 
designed for the analysis of 1.5 ml of blood on which a mechanic cell lysis is achieved with the SeptiFast 540 
Lys KIT MGRADE and the MagNALyser from Roche diagnostic prior DNA extraction using also a 541 
commercial kit provided by the same manufacturer. The assay contains an internal control that consist of 542 
a synthetic double-strand DNA, similar to the expected amplicon but with a distinct probe binding site.  543 
The analytic sensitivity is ranging from 3 to 30 CFU/ml for bacteria and is 100 CFU/ml for fungi (34; 544 
252). The experimental sensitivity (42.9% to 95%) and specificity (60% to 100%) of the SeptiFast are 545 
variable depending on the studies and on the patients characteristics (table 1) (21; 35).  546 
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Diagnosis of Infection in febrile neutropenia using the LightCycler SeptiFast  547 
From a group of 86 febrile neutropenic patients representing 141 episodes of fever, BC and SeptiFast 548 
detected approximately the same number of microorganisms: 44/141 (31.2 %) and 42/141 (29.8%), 549 
respectively. However, the association of BC and SeptiFast increases the rate of documentation from 550 
about 30% to 43% (61/141) which might be due to the fact that only 12 organisms where detected by both 551 
BC and SeptiFast (139). A similar observation was made by Mancini et al. on a study performed on 103 552 
samples from neutropenic patient with haematological diseases in which 20.4% of the samples were 553 
positive with BC and 33% using SeptiFast, with only 83% of correlation between the two methods (154). 554 
For Bravo et al., the agreement between BC and SeptiFast was 69% for neutropenic patients and 75% for 555 
patients from the intensive care unit (25). All these studies suggest that SeptiFast cannot replace BC but 556 
that the two techniques could be complementary (98; 139; 154; 161). Lamoth and colleagues suggested 557 
that the low sensitivity of SeptiFast was due i) to organisms absent from the SeptiFast analytic spectrum 558 
(40% of false negative) and  ii) to the cut-off that decrease the sensitivity for the detection of coagulase 559 
negative staphylococci or for streptococci and increased the rate of false negative (139). False negative 560 
results obtained for gram-negative cocci might also be explained by the inefficient lysis of these 561 
microorganisms (182) or to PCR inhibition in the case of high bacterial load. The adjustment of the 562 
experimental procedure and an adequate cut-off might increase the performance of the SeptiFast assay for 563 
neutropenic patients (139; 182). In a context of persistent fever, SeptiFast identified new pathogens in 564 
89% of the cases whereas BC identifies 8% of the pathogens (139). Similar results were obtains by von 565 
Lilienfeld-Toal et al. (241). In this study all the patients with a probable fungal infection had positive 566 
SeptiFast results for Aspergillus fumigatus. This suggests a potential added value of the SeptiFast assay 567 
for the detection of fungemia in neutropenic patients (35; 139; 154; 180; 241).  568 
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Diagnosis of infectious endocarditis 569 
A study performed on 63 patients with suspected endocarditis revealed a low sensitivity of the SeptiFast 570 
when compared to BC (34). Among 19 patients with positive blood culture at their admission, SeptiFast 571 
detected 8 bacteria (41% of sensitivity). Twenty-two patients had positive blood culture before their 572 
admission but because of efficient antibiotic treatment they had negative blood culture at the time of this 573 
study. Among them, SeptiFast detected only 3 bacteria (3/22) (34). In this study, SeptiFast did not detect 574 
any microbes for patients without any etiology (100% of specificity) (34). Because the low sensitivity of 575 
the SeptiFast was not due to pathogens that are not detected by this system, it could be due as discussed 576 
later to a low bacterial load. In another study involving 20 patients with endocarditis, SeptiFast performed 577 
on excised cardiac valves, displayed a higher sensitivity (95%), and specificity (100%) than culture 578 
(sensitivity 15% and specificity 100%) (81; 147). In patient with suspicion of Candida spp. endocarditis, 579 
SeptiFast was as sensitive as BC to detect fungal infection (141). 580 
Diagnosis of neonatal sepsis  581 
In a study performed on 1,673 pediatric samples (803 children), the detection rate of infection was higher 582 
with the SeptiFast (14.6%) than with BC (10.3%) which corresponded to a sensitivity of 85.0% and a 583 
specificity of 93.5% of the SeptiFast (153). The cumulative positive rate of BC and SeptiFast was 16.5%. 584 
Another study confirmed a higher sensitivity but a lower specificity of SeptiFast for the detection of late-585 
onset neonatal sepsis (127). 586 
Advantages and inconvenient of the LightCycler SeptiFast system 587 
The performances of the SeptiFast are variable depending on the studies. The overall sensitivity of the 588 
SeptiFast is not higher than the sensitivity of BC but together SeptiFast and blood culture increase the rate 589 
of microbial documentation of BSI. This suggests that the SeptiFast cannot replace blood cultures but that 590 
these two methods are complementary. One of the major advantage of the SeptiFast is the time to result 591 
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(<5hours). In a study performed on 114 consecutive patients with clinical evidence of sepsis the mean 592 
time to results for SeptiFast was less than 8 hours when BC mean time to positive result was 3.5 days and 593 
for negative result 5 days (218). In a study performed on patients of the emergency department with 594 
suspected sepsis, Schaub et al. Reported a median time to positivity of BC of 16 hours (without  the 595 
organism identification) (209). SeptiFast might be useful in case of a persistent bacteremia, for instance in 596 
neutropenic patient with persistent fever, for which SeptiFast often identified additional pathogens. There 597 
are a high number of studies on the performance of the SeptiFast. However, there is a need of 598 
interventional studies to clearly determine the clinical impact of this new technology. 599 
One of the limits of the SeptiFast is also the absence of exact quantification. Cut-off can be used for the 600 
interpretation of streptococci and coagulase negative staphylococci positive results in particular. This is 601 
expected to reduce the number of false positive results but might prevent the detection of low grade 602 
infections. In some studies performed in neutropenic patients, the sensitivity of SeptiFast for the detection 603 
of coagulase negative streptococci is decreased, which could be due to the fact that the cut-off were 604 
established for non-neutropenic patients. In contrast in pediatric studies SeptiFast leads to increasing 605 
number of false positive due to coagulase streptococci. Adding quantitative data to the SeptiFast has the 606 
potential to predict the severity of the sepsis (266).  607 
The HACEK group of fastidious bacteria (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella and 608 
Kingella) involved in a significant number of blood culture-negative bacteremia is not covered by the 609 
SeptiFast. For this reason SeptiFast is not sufficient by itself to diagnose all the bacteremia and alternative 610 
methods will still be required to cover the entire bacterial kingdom. Finally, in the context of an 611 
increasing number of multi-drug resistance organisms, it is a limitation that SeptiFast does not provide 612 
any data on the resistance profile of identified organisms excepted for MRSA but using an additional kit 613 
(table 1).  614 
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The MagicPlex Sepsis system  615 
The MagicPlex Sepsis system (Seegene, Seoul, Korea) is based on multiplexed real-time PCRs that can 616 
detect 90 pathogens at the genus level, 25 at the species level (19 bacteria and 6 fungi), and the resistance 617 
genes mecA, vanA and vanB directly from whole blood (1 ml). A specific nucleic acid extraction kit is 618 
used to enrich in microbial DNA. A first amplification is a screening that provides either (i) an  amplicon 619 
bank that consists of gram-negative bacteria and fungi or (ii) an amplicon bank that consists of gram-620 
negative bacteria (n=73) and resistance genes conferring resistance to methicillin (mecA) or vancomycin 621 
(vanA and vanB) . A second step is a screening for bacteria and fungi at the genus level and for the 622 
presence of resistance genes (time to result 5 hours).   623 
The performance of the MagicPlex system was compared to BC on 267 patients from the intensive care-624 
unit, from the haematology department and from the emergency department of a tertiary hospital, which 625 
revealed an agreement between the two methods of 73 % with no statistical difference between their 626 
sensitivity (30). For patient with antibiotic treatment, the sensitivity of the MagicPlex 65% was lower 627 
than the sensitivity of BC (71%); specificity was respectively 92% and 88% for each method. Another 628 
study performed on 140 patients with suspected BSI reported 37% of sensitivity and 77% of specificity of 629 
the MagicPlex when considering BC as gold standard (152).  630 
Additional studies are required to determine the exact potential of this device. This method is limited by 631 
the number of pathogen detected at the species level and by the absence of quantification. Another 632 
limitation is the absence of automation and the need of a specific extraction method which might makes it 633 
difficult to integrate in an automated molecular diagnostic laboratory.  634 
  635 
 636 
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3. PCR-Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) 637 
Principle, characteristics and performance of PCR/ESI-MS 638 
PCR-Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) is a technology that was initially 639 
developed to face bioterrorism threats or to run public health investigations. The aim was to provide a 640 
rapid method for the detection and identification of pathogens from various type of sample. The 641 
technology had to detect low quantity of a given pathogen even in polymicrobial samples and should 642 
include the detection of non cultivable or fastidious microorganisms. In addition, the technology should 643 
be able to detect known microorganisms as well as yet unknown pathogen.  Molecular diagnosis was 644 
chosen as it is fast and broad range. 645 
The PCR/ESI-MS approach is based (i) on the amplification of microorganisms DNA by multiple PCRs 646 
and (ii) on the identification of the organism(s) at the species or genus level through the analysis of the 647 
amplicon by ESI-MS (Electrospray Ionization Mass Spectrometry) (65; 123). Basically, PCR/ESI-MS 648 
consists in 5 steps: 1) extraction of the microorganism or sample DNA, 2) amplification of the DNA 649 
using multiple pairs of primers, 3) precise determination of the molecular mass of the amplicon(s) using 650 
ESI-MS, 4) deduction of the base composition of the amplicon(s) from the exact MW of the amplicon 5) 651 
identification of the pathogen(s) by integrating the informations obtained from several amplicon(s) (figure 652 
4) (66; 123).  653 
Before being applied to blood (see next paragraph) PCR/ESI-MS was first applied on bacterial colonies 654 
and on environmental samples. Practically, DNA amplification is based on multiple broad-range PCRs, 655 
which is more sensitive, than a single broad-range PCR based on degenerated primers. The primers are 656 
targeting conserved genomic region surrounding polymorphic regions (for instance DNA regions 657 
encoding for the 16S or the 23S rRNA). Moreover, these PCRs are devoid of fluorescent dye or probes, 658 
which allows high-level of multiplexing. DNA amplification may be performed in 96 well plate using the 659 
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following steps:  1) 95°C for 10 min, 2) 8 cycles of 95°C for 30 s, 48°C increasing of 0.9°C at each cycles 660 
for 30 s and 72°C for 30 s 3) 37 cycles of 95°C for 15 s, 56°C for 20 s, and 72°C for 20 s 4) final 661 
extension of 2 min at 72°C and hold at 4°C hold (73). Major innovation of PCR/ESI-MS is that the 662 
pathogen’s identification relies only on the base composition (A, C, G and T) of the amplicons (65; 123). 663 
The base composition is obtained by the integration of the exact mass of the amplicon, the length of the 664 
amplicon, the mass of each base and the complementarily rules of DNA (figure 4).  The choice of the 665 
PCR targets makes the base composition of one or more amplicon(s) sufficient for pathogen 666 
identification. The absence of Sanger sequencing dramatically reduces the time to result(s). Thus, ESI-MS 667 
provides the base composition of an amplicon in about 1 minute, the mass of the amplicon being 668 
determined by the time of flight (TOF). The base composition of the amplicon(s) is compared to a 669 
database providing the identification at the genus or at the species level with a score of probability (Q-670 
score) inferred by an ESI-MS triangulation software relying on multiple amplified regions. The Q-score 671 
integrates multiples parameters such as the number of primer pairs that gave an amplicon, the number of 672 
potential microorganism, the proximity of the base compositions to reference matches in the database. 673 
A set of 9 pairs of primers is used for the coverage of the bacteria kingdom. Four pairs are necessary for 674 
Candida species. Four additional pairs of primers have been designed to detect the resistance cassettes 675 
mecA, blaKPC, vanA and vanB. Using clinical samples (up to 1.25 ml) other than blood, PCR/ESI-MS 676 
displays good sensitivity and specificity. This includes environmental samples as well as clinical samples 677 
such as CSF (75; 76; 171) and respiratory tract samples (64; 91; 119). Compared to culture the PCR/ESI-678 
MS correctly identified 95.6% and 81.3% of the strains at genus level and species levels respectively. 679 
Among 395 respiratory samples, PCR/ESI-MS displayed 67.6% of agreement at the genus level and 680 
66.6% at the species level with culture. PCR/ESI-MS was able to identify fungi in 20.3% (35/172) of the 681 
respiratory specimens with a negative culture suggesting a better sensitivity than culture (217). A 682 
commercial kit available for the detection of viruses (38; 39; 48; 107; 135; 142; 185; 228; 231) has been 683 
shown to display higher performance than real-time PCR and microarrays (228). PCR/ESI-MS have also 684 
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been successful at identifying Mycobacterium species at the species level and at determining associated 685 
resistance genes using a panel of 8 PCRs (138; 160; 245). 686 
Thus, PCR/ESI-MS represents a universal method that may be applied to bacteria, viruses and fungi and 687 
that is expected to also identify any unknown species. Indeed, when primers are designed to identify all 688 
known members of characterized groups, they allow the detection of unknown or new emerging 689 
pathogens from these groups (138; 203; 204). This provides a potential for the rapid detection of 690 
emerging pathogens. In addition, PCR/ESI-MS can detect and identify all different pathogens present in 691 
polymicrobial samples with quantitative results.  This method can also be used on formalin or paraffin 692 
embedded tissue (216). 693 
Finally, PCR/ESI-MS has been extensively used for genotyping and serotyping of bacteria and viruses 694 
because of its accuracy to detect single nucleotides variations, which represents a tool for health care 695 
epidemiological investigation or outbreak follow-up.(23; 62-64; 67; 101; 102; 159; 190; 207; 214; 245; 696 
262). Such an accuracy of the PCR/ESI-MS naturally relies on a representative database and on its 697 
maintenance. 698 
Application of PCR/ESI-MS to the diagnosis of BSI directly from blood 699 
The first instrument that was developed was the TIGER (Triangulation Identification for the Genetic 700 
Evaluation of Risk) that allowed the detection of specific organisms even in polymicrobial samples (204). 701 
The Ibis T5000 instrument, the first commercial version of TIGER could identify up to 800 pathogens 702 
from whole blood (65; 261). When compared to blood culture, PCR/ESI-MS applied on 1 ml of whole 703 
blood displayed 50% of efficiency. A second commercial version, namely the PLEX-ID (Abbott), using 704 
up to 1.25 ml of blood, has been developed displaying good sensitivity and specificity on most of the 705 
samples which includes environmental samples as well as clinical samples such as CSF and sputum as 706 
said above (15; 38; 76; 91; 138). The first procedure of the PLEX-ID for whole blood consisted of a 707 
mechanic cell lysis, using beads, facilitated by the addition of proteinase K, SDS and eating at 56°C. 708 
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DNA purification was then achieved with magnetic silica beads and eluted in 250 μl of water at 70°C 709 
(137). The PCR is based on 9 pairs of primers for bacteria detection, 4 pairs for Candida species and 4 710 
pairs for detection of resistance cassettes (mecA, blaKPC, vanA, vanB). One additional pair of primer 711 
corresponds to the extraction control. The PLEX-ID gave 78.6% of agreement with blood culture over 712 
906 specimens taken from adult and pediatric patients (464 with positive blood culture and 442 with 713 
negative blood cultures). While 33 culture negative specimens were PLEX-ID positive, 97 culture 714 
positive specimens were PLEX-ID negative (137). In this study the estimated sensitivities of PCR/ESI-715 
MS was 85.9% when the estimated sensitivity of BC was 41.2%. To further increase the sensitivity of the 716 
detection directly from whole blood a second version of the PLEX-ID that could analyse up to 5 ml of 717 
blood has been developed. In this version, the increased sample volume was associated with a DNA 718 
extraction method and PCR conditions optimized for whole blood samples (13).  Practically, 5 ml of 719 
whole blood were lysed in presence of  665 μl of a commercial buffer (100 mM Tris solution containing 720 
guanidinium thiocyanate and detergent), 145 μl of BSA 10% containing a pumpkin DNA extraction 721 
control), and yttria-stabilized zirconium oxide beads (166).  After the removal of lysed red-blood cells by 722 
centrifugation the nucleic acid were extracted from the supernatant using silica-coated magnetic beads. 723 
Thirty microliters of the eluate were used for the PCR with 25 μl of PCR master mix containing the pool 724 
of primers pairs (137). Rather than trying to remove the excess of human DNA, PCR conditions were 725 
defined in the context of high concentration of human DNA. This was achieved by testing multiple PCR 726 
conditions by modulating Mg2+, primers and polymerase concentration and annealing temperature in the 727 
presence of 12 μg of human DNA (13; 73). In this background, high primers concentration (750 μM) 728 
together with high polymerase concentration (2.2 units per reaction) resulted in a PCR yield of 86% of the 729 
yield when 1 μg human DNA was present. Modulating Mg2+ concentration or the annealing temperature 730 
had only a weak impact on the PCR yield. This procedure was then evaluated in a prospective study 731 
involving 331 patients with suspected BSI (13). For each patient 2 blood bottles (one aerobic and one 732 
anaerobic) were inoculated with 5 ml of whole blood and an additional blood sample was collected for 733 
PCR/ESI-MS analysis from the same venipuncture (137). The PCR/ESI-MS displayed 83% of sensitivity 734 
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and 94% of specificity as compared to BC. Interestingly, this corresponded to 35 positive specimens 735 
(10.6%) by PCR/ESI-MS and 18 positive by culture (5.4%). In the absence of any method to investigate 736 
the discrepant results, a second aliquot was analysed using PCR/ESI-MS, which confirmed almost all the 737 
identifications and increased the sensitivity of PCR/ESI-MS to 91% and the specificity to 99%, were (13). 738 
The limit of detection of the PCR/ESI-MS method developed by Bacconi et al. is 16 CFU per mL for S. 739 
aureus, K. pneumoniae and E. faecium, and 4 CFU per mL for C. albicans. It is generally admitted, based 740 
on plating methods, that the number of bacteria circulating during BSI is between 1 and 10 CFU per ml 741 
(105; 132; 133; 243; 251). The analysis of the data from the literature performed by Bacconi and 742 
colleagues estimated that the amount of bacterial DNA in blood during a BSI vary between 103 to 104 743 
genomes copies per ml (13). This difference could be due to the fact that plating methods reflect the 744 
number of cells that survive the procedure rather than the number of circulating cells. Molecular diagnosis 745 
directly from blood could detect also free DNA, DNA resulting from dead bacterial cells and bacterial 746 
DNA present within phagocytes, which may explain the high performance of the PLEX-ID on whole 747 
blood. However, this extremely high sensitivity may lead to contamination by DNA. For this reason, the 748 
use of ultra-clean reagents associated with molecular biology laboratory practices is mandatory. 749 
PCR/ESI-MS is also a promising tool for the diagnostic of blood culture negative BSI. Indeed, among 750 
464 patients with positive blood cultures and 442 patients with negative blood culture, 33 culture negative 751 
cases were detected positive by PCR/ESI-MS and these cases were demonstrated to be true BSI based on 752 
the analysis of the clinical presentation (137). Using primers and probe specific of Ehrlichia chaffeensis 753 
targeting the 16S gene and a genus specific set of primers and probes Eshoo and colleagues reported 754 
18.8% of PCR/ESI-MS positive specimen of whole blood among 213 blood samples from patients with 755 
suspicion of ehrlichiosis (73). From the same pool of specimen, PCR/ESI-MS identified Rickettsia 756 
rickettsii from 4 samples and Neisseria meningitidis from one samples. 757 
PCR/ESI-MS was designed to detect all pathogens present in a mixed microorganism populations (118; 758 
205). This is also true for polymicrobial blood culture since PCR/ESI-MS could identify 29 bottles with 759 
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mixed populations out of 234 positive BC bottles (125). A quantitative analysis performed using an 760 
internal control helps at (i) interpreting results for polymicrobial samples and (ii) identifying true positive 761 
versus contaminating organisms (137). Further studies are required to determine if the quantification 762 
could also help at defining the severity of the infection. 763 
In conclusion, the PLEX-ID, which provides reliable results in less than 6 hours, is a versatile system that 764 
may be directly used on blood starting from 5 ml of samples and that represents a complementary 765 
approach to blood cultures. 766 
MOLECULAR DETECTION OF ANTIMICROBIAL RESISTANCE 767 
DURING BLOOD STREAM INFECTIONS  768 
BSI is characterised by a high level of morbidity and mortality that increases with the delay in the 769 
introduction of an efficient anti-infectious therapy (58; 82; 90; 113; 148; 149; 157; 232). The rapid 770 
identification of the pathogen gives a first indication on the effectiveness of the empiric therapy. 771 
However, rapid information on the resistance profile of the agent of a BSI, would allow to better adjust 772 
the empirical treatment.    773 
1. Rapid PCR Based-methods for resistance detection from positive blood 774 
cultures 775 
Detection of resistance mechanisms of gram-positive bacteria 776 
Staphylococcus aureus is a significant agent of both community-acquired infections and nosocomial 777 
infections (256). In recent years, it has been observed an alarming increase of the percentage of 778 
methicillin resistant Staphylococcus aureus (MRSA) a drug resistant pathogen associated with significant 779 
increase of the mortality (49; 50; 169; 170; 263), which explains that many rapid methods are now 780 
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available to simultaneously identify S. aureus and detect the mecA gene associated with methicillin 781 
resistant (table 1) (71; 77).  782 
The GeneXpert MRSA/SA BC Assay (Cepheid, Sunnyvale, CA) is a good example of such dual detection 783 
method based on real-time PCR for the identification of S. aureus and the detection of the mecA gene. 784 
The analysis may be performed directly from positive BC in about 1 hour and was validated both in adult 785 
and pediatric patients with BC positive for gram-negative cocci in cluster with 100% of sensitive and 99.5 786 
to 100 % of specificity (45; 221). The GeneXpert MRSA/SA BC Assay dramatically reduced the time to 787 
detection of S. aureus and has an impact on the detection of MRSA (figure 2) (45; 54; 140; 208). 788 
Also based on real-time PCR, another rapid PCR-based assay, the StaphSR assay (BD GeneOhm, San 789 
Diego, CA), can identify and differentiate methicillin-susceptible S. aureus (MSSA) and methicillin-790 
resistant S. aureus (MRSA) from positive blood cultures in about 1.5 h with an analytical sensitivity of 15 791 
DNA copies per reaction mixture which correspond to 103 DNA copies per ml (117; 222). The assay was 792 
validated on BC with a predominance of gram-negative cocci in cluster showing 95.6% -100% of 793 
sensitivity and 95.3% - 98.4% specificity for the detection of MRSA (97; 130; 140; 222). Discrepant 794 
results are mainly explained by mixed culture or inhibition of the PCR. Negative MRSA detection is also 795 
due to MREJ variants that contain the staphylococcal cassette chromosome mec (SCCmec) without the 796 
mecA gene (219). 797 
The StaphPlex system (Genaco Biomedical Products, Huntsville, AL, USA) is based on multiple PCRs 798 
(18 target genes) and microarray analysis for the identification of staphylococci at species-level, for the 799 
detection of resistance genes and for the detection of the Panton-Valentine leukocidin (PVL) with a time 800 
to result of about 5 hours. The overall accuracy for the detection of staphylococci at the species level from 801 
mono-bacterial or poly-bacterial culture was 91.7% when compared to conventional methods (230). The 802 
StaphPlex exhibited 100% of sensitivity and 95.5% to 100.0% of specificity for the detection of the mecA 803 
gene. Similar results were obtained for the detection of the PVL gene (230). 804 
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The FilmArray (Idaho Technology, Salt Lake City, UT, USA) is another PCR-based system that can 805 
detect the S. aureus mecA gene as well as the vanA and vanB genes implicated in vancomycin resistance 806 
in Enterococcus species (16; 192). The FilmArray system exhibits a high sensitivity and specificity 807 
(100%) for the detection of the mecA gene from S. aureus positive culture with (16; 19; 196). Another 808 
study reported 96% of sensitivity and 98.9% of specificity for the detection of the mecA gene (6). For the 809 
detection of the vanA and vanB genes in Enterococcus spp., Blasche et al. reported only 85% of 810 
specificity of the FilmArray system when compared to BC (19). In this study, the FilmArray detected a 811 
van gene in 2 Enterococcus strains that where found vancomycin sensitive by culture based methods. The 812 
second strain was actually an Enterococcus casseliflavus strain bearing the vanC gene. During the 813 
development of the system, more resistance markers have been successfully tested (19).  814 
The microarray of the Verigene gram-negative system (Northbrook, IL, USA) includes probes for the 815 
detection of the mecA gene with 98.6% of sensitivity and 94.3% of specificity (26). This system also 816 
contains probes for the detection of VRE with 100% of sensitivity and specificity in a prospective study 817 
from positive BC (26). 818 
The major weakness of the nucleic acid methods is to assign the resistance gene to the correct 819 
microorganism in the case of mixed cultures. This is particularly limiting for the detection of the mecA 820 
gene in a mix culture of S. aureus that would contain contaminating coagulase negative staphylococci for 821 
instance (26). 822 
Detection of resistance mechanisms of gram-negative bacteria 823 
Gram-negative bacteria can exhibit resistance mechanisms to multiple antibiotics, representing a major 824 
problem for the treatment of infections. In particular Enterobacteriaceae have developed multiple 825 
resistance mechanisms to cephalosporins, such as ESBL.  This had presented the carbapenem as 826 
alternative for the treatments of severe infections involving Enterobacteriaceae and non-fermentative 827 
bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. However, resistance to 828 
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carbapenem may also occur. It might be caused by a reduced permeability with loss of porins, by the 829 
over-expression of efflux pumps or alternatively by the production of carbapenem degrading enzymes, 830 
namely carbapenemases. The emergence of carbapenem resistance strains and their spread worldwide is 831 
alarming both from a therapeutic point of view and from an epidemiological point of view.  Nucleic acid 832 
detection systems are focusing on the blaKPC gene that encode for K. pneumoniae carbapenemase. This is 833 
the case of the FilmArray system that includes primers targeting the blaKPC gene (6; 17; 19; 196) and the 834 
Verigene gram-negative system that contain probes for the detection of the blaKPC (17). More studies 835 
involving KPC positive strains are needed to determine the sensitivity and specificity of these systems. 836 
Moreover, future tools should aim at detecting a broader range of genes encoding SBL and/or 837 
carbapenemases. 838 
2. Resistance detection from positive blood culture using MALDI-TOF MS 839 
The use of the MALDI-TOF MS for the detection of resistant strains was first proposed for the distinction 840 
between MRSA and MSSA colonies (68). However, recent developments are mainly directed toward 841 
gram-negative bacteria in which The MALDI-TOF MS may detect antibiotics degrading proteins such as 842 
carbapenemases. Practically a bacterial inoculum is incubated with ertapenem. The MALDI-TOF MS 843 
analysis performed on the supernatant is used to determine the shift of two specific peaks associated with 844 
the degradation of the carbapenem. This method has been validated on bacterial colonies with 100% of 845 
sensitivity and 100% of specific for the detection of carbapenemase producing strains (240). Carvalhaes 846 
and colleagues have proposed a method to be used directly from bacterial pellet obtain from positive BC, 847 
which is able to identify 72.4% (21/29) of the carbapenemase-producing isolates after 4 h of incubation 848 
(33). MALDI-TOF MS represents an alternative for the detection of carbapenemase from positive BC that 849 
has the advantage, over PCR, to provide a phenotypic result.   850 
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3. Resistance detection directly from whole blood 851 
As said earlier, the detection of resistance genes directly from blood would considerably impact the 852 
choice of the therapy. Four primer set of the PLEX-ID system are used to detect the resistance cassettes 853 
mecA, vanA and vanB and blaKPC, (70; 247). It has to be noted that the PLEX-ID system can also detect 854 
the presence of the S. aureus Panton-Valentine leukocidin toxin (PVL) (247). PCR/ESI-MS was also 855 
shown to be successful at identifying the mutations in gyrA and parC genes involved in Acinetobacter 856 
baumannii resistance to quinolones (114; 115). In the case of mixed population, quantitative analysis 857 
could help at associating a resistance gene to the corresponding pathogen. The MagicPlex system can 858 
detect three resistance markers (mecA, vanA, vanB) directly from blood (152). From their study, Carrara 859 
et al. failed to detect six MRSA strains out of ten using the MagicPlex system (30). The VYOO system 860 
can detect five resistance genes: mecA, vanA, vanB β-lactamase blaSHV, β-lactamase blaCTX-M. However 861 
there is a lack of studies reporting the sensitivity of this method. Finally, the SeptiFast system contains 862 
primers for the detection of mecA only (table 1). 863 
Although molecular methods have the ability to detect some resistance genes, more studies are required to 864 
determine their performances and their clinical impact. In addition, increasing the number of available 865 
resistance markers would be an advantage.    866 
 867 
CONCLUSIONS AND FUTURE DIRECTIONS  868 
Nucleic acid methods have succeeded to overcome most of the obstacle that limited the sensitivity of the 869 
detection of pathogen from blood containing sample. The sensitivity and specificity are now adequate for 870 
the use in diagnostic laboratory. 871 
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One major problem for the determination of the performances of new molecular methods is the fact that 872 
BC associated with traditional identification methods remains the gold-standard. In this context, many 873 
assays display extremely high analytic sensitivity but limited apparent specificity due to a limited 874 
correlation with BC.  This could be overcome by the use of other evaluation methods to challenge BC. In 875 
their study, Bacconi and colleagues showed that 16S sequencing is not an appropriate method to be used 876 
as reference for the evaluation of PCR/ESI-MS. Indeed, only 2 of the 35 samples positive using the 877 
PCR/ESI-MS were found positive by 16S sequencing when the sequencing was performed on the same 878 
material. Thus one of the limits to develop new methods for the diagnostic of BSI is that blood culture 879 
remains the gold standard (13). To compare the performance of blood culture and other methods, clinical 880 
presentations and local epidemiology should be taken into account in order to properly investigate 881 
discrepant results (13; 137). Nevertheless the poor correlation between conventional BC-based methods 882 
and some new molecular methods suggest that different pathogens are detected by these two methods and 883 
that these diagnostic tools should be complementary. Moreover BC could not be replaced since the 884 
availability of a strain in pure culture is mandatory to precisely test antibiotic susceptibility of bacteria.   885 
Although new molecular methods are really appealing, further studies are still needed to determine their 886 
impact on the management of patients with BSI (175). For instance, there is a lack of study that addresses 887 
the impact on antibiotic stewardship. While most of the studies try to give with precision the 888 
performances of the new molecular methods, it is not yet clear how these methods can be integrated in a 889 
molecular laboratory.  This is particularly true as none of the method would replace BC. Some practical 890 
details have to be investigated. Thus, the number of samples, the number of venipuncture and the 891 
frequency of the sampling for molecular diagnostic has to be addressed. Otherwise, informations 892 
(routinely provided by the BC) on the likelihood of an infection (such as a possible catheter infection) 893 
versus a contamination would be missing. 894 
Molecular methods can also be helpful for organisms that are phenotypically closely related or for rare 895 
organisms. However, because some genetically closely related organisms cannot be discriminated on the 896 
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basis of molecular methods such as E. coli/Shigella (59; 210) or group mitis streptococci/Streptococcus 897 
pneumoniae (126; 224; 227), phenotypic distinction methods remain crucial. In the same manner the 898 
accuracy of many molecular methods is based on their databases, which have to be maintained by adding 899 
nucleic acid sequences or mass-spectrum obtained for new clinical isolates or rare organisms. For nucleic 900 
acid methods, it is also crucial to achieve a follow-up of the emergence of SNP or mutations 901 
(insertion/deletion) that could affect the hybridization of specific primers and probes. One solution would 902 
be to rely on multiple targets (sequence or gene) for the identification of a given organism (120; 222).  903 
As already stressed earlier the Gram staining remains mandatory for BC based methods since (i) it can 904 
help at disclosing poly-microbial infection, (ii) it serves as a quality control and (iii) it sometimes helps 905 
identification thanks to specific phenotypic traits. Nevertheless the presence of a single morphotype on 906 
the Gram staining, does not exclude the presence of multiple organisms, since Enterobacteriaceae often 907 
exhibit a similar Gram staining morphotype. 908 
Regarding poly-microbial identification, the quantification provided by some nucleic-acids based 909 
methods, can be helpful at determining the significance of the respective organisms. Another research 910 
focus is the attempt to provide clinical scores that would predict the severity of bacteremia (78; 195). The 911 
time to positivity of blood BC has been proposed as a criterion for BSI severity (7; 113; 129).  Similarly, 912 
quantification could provide some insight on the severity of the BSI. Thus, analysis of 250 whole-blood 913 
samples from 20 adult patients (13 survivors and 7 nonsurvivors) with culture-proven MRSA showed that 914 
the levels of mecA DNA was higher in the nonsurvivors (5.48 copies/ml) than in the survivors (4.58 log 915 
copies/ml P= 0.003, two-tailed Mann-Whitney U test). This suggested that the level of mecA DNA in 916 
blood could potentially be used to monitor MRSA bacteremia and evaluate responses to therapy (109). 917 
Similarly a positive correlation has been found between the level of Streptococcus pneumoniae DNA 918 
monitored by real-time PCR and the need of mechanical ventilation, the risk of septic shock and of death 919 
(32; 198). Another study performed with the SeptiFast on 94 patients reported that the median cycle 920 
threshold (Ct) value was 16.9 for patients with severe septic choc and 20.9 for patients with non-severe 921 
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sepsis and that Ct value <17.5 correlated with more positive blood culture and longer hospital stays (80; 922 
266).  923 
The quantification can also help at identifying the presence of a contaminant. In this context, the threshold 924 
of the quantitative results becomes an important parameter to limit the number of false positive and false 925 
negative results.  Molecular solutions devoid of quantitative or at least semi-quantitative analysis will 926 
render the interpretation of the positive results difficult. The interpretation of poly-microbial detection as 927 
well as mono-bacterial ones is facilitated by the fact that PCR/ESI-MS gives is a quantitative analysis 928 
performed using an internal control. This can also helps at identifying true positive versus contaminating 929 
organisms (137) and at determining the relevance of each pathogen for mixed infections (75). Further 930 
studies are required to determine if the quantification could also help at defining the severity of the 931 
infection. 932 
Regarding persisting bacteremia in the context of an ongoing treatment, molecular methods have been 933 
able to rapidly detect new organisms that BC could not detect. However, nucleic-acid methods are not 934 
adequate for the follow-up of persistent infections because they can detect the persistence of DNA from 935 
dead organisms rather than true persisting organism. Therefore, many methods are now being developed 936 
to detect only DNA from living organisms (1; 172). This could be of particular interest to monitor the 937 
efficiency of an antibiotic treatment (29; 248). 938 
Indication on the presence of resistance genes is an important added value of some molecular methods 939 
being especially helpful at identifying risk of treatment failure. Development should focus in the 940 
integration of more molecular markers. Molecular diagnosis may also detect the presence of virulence 941 
genes, which helps predicting the severity of infection. Thus the StaphPlex system helps identifying 942 
staphylococci at the species-level and detect resistance genes as well as the Panton-Valentine leukocidin 943 
(PVL), excellent sensitivity (100%) and specificity (>95.5%) (230). 944 
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In conclusion, molecular diagnosis has significantly improved the diagnosis of BSI due to the reduction 945 
of the time to result and to the high sensitivity and specificity. In particular the MALDI-TOF MS is a 946 
revolution for the diagnosis of BSI from positive BC. To impact the management of patients suffering of 947 
BSIs, microbiologist and clinicians should imagine new laboratories and algorithms that associate these 948 
new culture-independent and culture dependant molecular methods with conventional methods in the aim 949 
to get the benefits from both diagnosis methods.            950 
 951 
  952 
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Table 1: Commercially available molecular systems for the microbial identification of pathogen 1743 
during BSI. Adapted from (174; 175) 1744 
 1745 
SYSTEM 
(MANUFACTURER) 
METHODS TIME TO 
RESULT 
MICROORGANISM 
COVERAGE 
RESISTANCE AND 
VIRULENCE 
MARKERS 
SENSITIVITY, 
SPECIFICITY AND 
CORRELATION WITH 
CONVENTIONAL 
METHODS  
REFERENCES 
IDENTIFICATION FROM 
POSITIVE BLOOD-CULTURE 
    
PNA FISH and  QuickFISH 
(AdvanDx, Wolburn, MA)  
FISH  <1-3 hours  4 gram-negative  
4 gram-negative  
5 fungi  
none  97-100% 
90-100% 
96-99% 
(31; 55; 56; 85; 103; 
106; 167; 220; 225) 
 
AccuProbe 
(Gen-Probe, San Diego, CA, 
USA)  
FISH  <1 hour  S. aureus 
Enterococcus spp. 
S. pneumoniae  
Streptococcus group A 
Streptococcus group B  
none 80.8-100% 
98.7-100% 
nr 
(9; 151)  
Verigene 
(Nanosphere, Northbrook, IL, 
USA)  
Microarray  2.5 hours  12 gram-negative  
 9 gram-negative  
mecA, vanA/B,  
blaKPC , blaNDM, CTX-
M,VIM,IMP,OXA12  
81-100% 
98-100% 
nr 
(5; 14; 17; 26; 60; 
155; 165; 226; 227; 
234) 
Prove-it Sepsis  (Mobidiag, 
Finland)  
Microarray  3.5 hours  60 bacteria  
13 fungi  
 mecA  95 % 
99 % 
nr 
(233) 
FilmArray 
(Idaho Technology, Salt Lake 
City, UT, USA)  
Multiplex PCR  1 hour 8 gram-negative  
11 gram-negative  
5 fungi  
mecA, vanA/B,  
blaKPC 
97-95% 
91-98% 
nr 
(6; 19; 181; 196) 
Xpert MRSA/SA BC 
(Cepheid, Sunnyvale, CA, USA)  
Real-time PCR  1 hour  S. aureus  mecA  100% 
99-100% 
nr 
(45; 54; 140; 208; 
221) 
StaphSR assay 
(BD GeneOhm, San Diego, CA, 
USA)  
Multiplex PCR  1-2 hours  S. aureus  mecA  96-100% 
95-98% 
nr 
(97; 130) 
StaphPlex 
(Genaco Biomedical Products, 
Huntsville, AL, USA) 
Multiplex PCR + 
Microarray  
5 hours  S. aureus  mecA (+ PVL)  100% 
95-100% 
92% 
(230) 
MALDI-TOF MS 
Bruker  Daltonics (Bremen, 
Germany)  or bioMérieux 
(Marcy l’Etoile, France)  
Mass-
spectrometry  
<1 hour  <1000a not in routine - 
- 
76-99% 
(42; 52; 156; 158; 
193; 194; 224) 
IDENTIFICATION FROM WHOLE 
BLOOD 
    
SepsiTest 
(Molzym, Bremen, Germany)  
Broad range PCR 
+ sequencing  
6 hours  
(1-10b ml) 
>345 bacteria and fungi  none   21-87% 
85-96% 
nr 
(145; 152; 177; 200; 
212; 250) 
SeptiFast 
(Roche Molecular System, 
Germany ) 
Multiple broad-
range real time 
PCR  
3.5-5 hours  
(1.5 ml) 
6 Gram positive 
8 gram-negative  
5 fungi  
mecA b 43-95% 
60-100% 
43-83% 
(25; 35; 53; 80; 95; 
124; 127; 139; 143; 
145-147; 153; 154; 
161; 164; 182; 186; 
197; 244) 
MagicPlex 
(Seegene, Seoul, Korea)  
Multiple PCR+ 
multiplex real 
time PCR  
3-5 hours  
(1ml) 
21 bacteria at species 
level  (90 at genus 
level) 
6 fungi  
mecA, vanA/B  37-65% 
77-92% 
73% 
(30; 152) 
VYOO 
(SIRS-Lab, Jena, Germany)  
Multiplex PCR + 
electrophoresis 
8 hours 
(5ml)  
14 Gram positive 
18 gram-negative  
7 fungi  
none nr 
nr 
70% 
(20; 84; 212) 
PLEX-ID  
(Abbott Molecular, Des 
Plaines, IL)Laboratories, IL, 
USA)  
Multiplex broad-
range PCR +  ESI-
MS  
6 hours 
(1.25-5 c  ml)  
up to 800  
(Gram positive, Gram 
negative, fungi)  
mecA,  blaKPC , 
vanA/B  
50-91%d 
98-99% 
79-97% 
(13; 166) 
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a Dependant on the mass-spectrum database 1746 
b With an additional kit 1747 
c For the latest version 1748 
d depending on the volume 1749 
nr=non reported 1750 
  1751 
83 
 
 1752 
Figure 1: Different molecular technologies used for the detection and identification of microbes 1753 
during bloodstream infections. Molecular methods for the diagnosis of BSI include nucleic acid-based 1754 
methods and non-nucleic acid-based.  Nucleic acid amplification-based techniques can be applied on 1755 
positive blood cultures or used directly on blood whereas non nucleic acid amplification-based techniques 1756 
such as FISH (fluorescent in situ hybridization) and microarray or non-nucleic acid based methods such 1757 
as MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry) 1758 
can be used only on positive blood culture. Adapted from (150). 1759 
  1760 
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 1761 
 1762 
Figure 2: Conventional and molecular methods for the identification of microorganisms from 1763 
positive blood culture. When a blood culture is detected as positive several strategies are available to 1764 
identify the incriminated microorganism after the initial Gram staining: (1) Identification directly from 1765 
the positive blood culture using nucleic acid-based methods, (2) Identification after microbe’s enrichment, 1766 
namely a purified bacterial pellet suitable for MALDI-TOF MS analysis and some automated 1767 
identification/AST approaches such as Vitek2 and Phoenix and rapid biochemical tests HMRZ and 1768 
ESBLNP (3) Identification after a subculture; to date the automated system Vitek2 has been validated on 1769 
short subculture as well as the rapid biochemical tests HMRZ and CARNP;  long subculture are suitable 1770 
for any type of analysis including phenotypic characterization, automated systems such as Vitek2, 1771 
Phoenix and MicroScan WalkAway as well as PCR followed by sequencing. Adapted from (174). 1772 
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 1773 
 1774 
  Figure 3: Microbial identification from positive blood culture using MALDI-TOF MS. The sample 1775 
that is deposited on the MALDI-TOF multi-well plate can be a bacterial pellet obtained by centrifugation 1776 
and erythrocytes lysis. Alternatively, the sample can be bacteria obtained after a subculture. Proteins are 1777 
then extracted and embedded in a matrix directly on the multi-well conductive metal plate and submitted 1778 
to the MALDI-TOF MS, which separate the proteins according to their MW and their charges. This 1779 
generates a mass spectrum (MS) which, in a second stage is compared to a database of spectra. This 1780 
analysis provides the identification of the microorganism with a confidence score, which allows 1781 
acceptation at the species or at the genus level. The identification is interpreted according to the Gram 1782 
staining and to the clinical presentation. Adapted from (52).  1783 
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 1786 
Figure 4: Schematic workflow of PCR/ESI-MS. (a) Nucleic-acids are extracted from the sample, 1787 
directly from whole blood, and (b) amplified by multiple PCR using multiple pairs of primers; each 1788 
colour represents a different primer. After amplification, the molecular mass of the amplicon(s) is 1789 
precisely determined using ESI-MS (c, d and e), from which (f) the base composition of the amplicon(s) 1790 
is deduced. Finally, (g) informations - base composition - obtained from one or more amplicon(s) are 1791 
compared with a database, which provides the identification with a confidence score. Adapted from (123). 1792 
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